SAB Biotherapeutics (NASDAQ:SABS) Given Buy Rating at Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research note issued on Tuesday, Benzinga reports. They currently have a $25.00 price target on the stock. Chardan Capital’s target price points to a potential upside of 443.48% from the company’s previous close.

Separately, HC Wainwright decreased their price target on SAB Biotherapeutics from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd.

SAB Biotherapeutics Price Performance

Shares of SABS stock opened at $4.60 on Tuesday. SAB Biotherapeutics has a 12-month low of $4.00 and a 12-month high of $14.50. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.45 and a quick ratio of 5.45. The business has a 50 day simple moving average of $4.94 and a 200 day simple moving average of $3.12.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SABS. RTW Investments LP acquired a new stake in SAB Biotherapeutics in the fourth quarter worth approximately $6,310,000. BVF Inc. IL bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth $6,310,000. Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at $1,259,000. Vanguard Group Inc. boosted its stake in SAB Biotherapeutics by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 996,132 shares of the company’s stock valued at $685,000 after buying an additional 19,194 shares in the last quarter. Finally, Pathstone Family Office LLC acquired a new position in SAB Biotherapeutics during the third quarter worth about $319,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.